Literature DB >> 15345134

Human embryonal carcinoma stem cells: models of embryonic development in humans.

S A Przyborski1, V B Christie, M W Hayman, R Stewart, G M Horrocks.   

Abstract

There are few reliable experimental systems available to study the molecular mechanisms that govern human embryonic development. Embryonal carcinoma (EC) cells are pluripotent stem cells derived from teratocarcinomas and are considered the malignant counterparts of human embryonic stem (ES) cells. Several of the existing human EC stem cell lines provide robust and simple culture systems to study certain aspects of cellular differentiation in a manner pertinent to human embryogenesis. Here we review the strategies used to derive and characterize the established and recognized human EC stem cell line TERA2.cl.SP12. Furthermore, we demonstrate the value of human EC stem cells as a model of early development and focus on cell fate determination in the embryonic ectoderm.

Entities:  

Mesh：

Year:  2004        PMID： 15345134     DOI： 10.1089/scd.2004.13.400

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN： 1547-3287            Impact factor:   3.272


  23 in total

1.  Comparative epigenetic analysis of Oct4 regulatory region in RA-induced differentiated NT2 cells under adherent and non-adherent culture conditions.

Authors:  Raha Favaedi; Maryam Shahhoseini; Mohammad Reza Akhoond
Journal:  Mol Cell Biochem       Date:  2011-12-09       Impact factor: 3.396

2.  Tumourigenic characteristics of embryonal carcinoma cells as a model for studying tumour progression of human embryonic stem cells.

Authors:  S Yang; G Lin; L Deng; G-X Lu
Journal:  Cell Prolif       Date:  2012-08       Impact factor: 6.831

3.  The NSL Chromatin-Modifying Complex Subunit KANSL2 Regulates Cancer Stem-like Properties in Glioblastoma That Contribute to Tumorigenesis.

Authors:  Nazarena E Ferreyra Solari; Fiorella S Belforte; Lucía Canedo; Guillermo A Videla-Richardson; Joaquín M Espinosa; Mario Rossi; Eva Serna; Miguel A Riudavets; Horacio Martinetto; Gustavo Sevlever; Carolina Perez-Castro
Journal:  Cancer Res       Date:  2016-07-12       Impact factor: 12.701

4.  Applications of novel bioreactor technology to enhance the viability and function of cultured cells and tissues.

Authors:  H W Hoyle; L A Smith; R J Williams; S A Przyborski
Journal:  Interface Focus       Date:  2020-02-14       Impact factor: 3.906

5.  Assessment of pluripotency and multilineage differentiation potential of NTERA-2 cells as a model for studying human embryonic stem cells.

Authors:  Rajarshi Pal; Geeta Ravindran
Journal:  Cell Prolif       Date:  2006-12       Impact factor: 6.831

6.  Directed differentiation of mouse P19 embryonal carcinoma cells to neural cells in a serum- and retinoic acid-free culture medium.

Authors:  Isha Verma; Polani B Seshagiri
Journal:  In Vitro Cell Dev Biol Anim       Date:  2018-07-20       Impact factor: 2.416

7.  Nucleoside drugs induce cellular differentiation by caspase-dependent degradation of stem cell factors.

Authors:  Tanja Musch; Yuva Oz; Frank Lyko; Achim Breiling
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

8.  Directed differentiation of embryonic stem cells into bladder tissue.

Authors:  Siam Oottamasathien; YongQing Wang; Karin Williams; Omar E Franco; Marcia L Wills; John C Thomas; Katrina Saba; Ali-Reza Sharif-Afshar; John H Makari; Neil A Bhowmick; Romano T DeMarco; Susan Hipkens; Mark Magnuson; John W Brock; Simon W Hayward; John C Pope; Robert J Matusik
Journal:  Dev Biol       Date:  2007-01-12       Impact factor: 3.582

Review 9.  Disease modeling using human induced pluripotent stem cells: lessons from the liver.

Authors:  Richard L Gieseck; Jennifer Colquhoun; Nicholas R F Hannan
Journal:  Biochim Biophys Acta       Date:  2014-06-02

10.  Integrating human stem cell expansion and neuronal differentiation in bioreactors.

Authors:  Margarida Serra; Catarina Brito; Eunice M Costa; Marcos F Q Sousa; Paula M Alves
Journal:  BMC Biotechnol       Date:  2009-09-22       Impact factor: 2.563
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.